20 results
8-K
EX-99.1
MRSN
Mersana Therapeutics Inc
9 May 24
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
7:10am
research and CMC activities.
Research and development (R&D) expenses for the first quarter of 2024 were $18.7 million, compared to $47.3 million … for the same period in 2023. Included in the first quarter of 2024 R&D expenses were $2.5 million in non-cash stock-based compensation expenses. The year-over
8-K
EX-99.1
MRSN
Mersana Therapeutics Inc
28 Feb 24
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
7:07am
in the fourth quarter of 2022.
Research and development (R&D) expenses for the fourth quarter of 2023 were $21.5 million, compared to $45.7 million … for the same period in 2022. Included in the fourth quarter of 2023 R&D expenses were $2.2 million in non-cash stock-based compensation expenses
8-K
EX-99.1
MRSN
Mersana Therapeutics Inc
7 Nov 23
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
7:18am
and development (R&D) expenses for the third quarter of 2023 were $30.5 million, compared to $50.6 million for the same period in 2022. The decline in R&D expenses … in third quarter 2023 R&D expenses were $2.2 million in non-cash stock-based compensation expenses.
General and administrative (G&A) expenses
8-K
0es cpta1l72do18sm4
6 Sep 23
Departure of Directors or Certain Officers
7:08am
8-K
EX-99.1
y6geiv25ufoi ief
8 Aug 23
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
8:04am
8-K
EX-99.1
9b5kq6y
9 May 23
Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
7:11am
8-K
EX-99.1
8g322
7 Nov 22
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
7:10am
8-K
EX-99.1
id7276lvt c96
8 Aug 22
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
4:11pm
8-K
EX-99.1
ao6plb2sh25td
9 May 22
Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
7:08am
PRE 14A
pj4gj5ot wo3juz3
18 Apr 22
Preliminary proxy
4:10pm
8-K
EX-99.1
ofzcpjet lpt
10 May 21
Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
5:00pm
8-K
EX-99.1
2807v
11 Mar 21
Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors
9:17am
8-K
EX-99.1
88pg8gi4b8grx ge7r6
28 Feb 19
Other Events
4:06pm
- Prev
- 1
- Next